A quiet shift in policy has unleashed a dramatic surge in abortions across the nation. Since 2020, the numbers have steadily climbed, fueled by a change in how a key medication is accessed – a change that could be reversed with a single decision.
The catalyst? A COVID-era policy enacted by the Biden administration that permits abortion pills to be prescribed through telehealth and delivered directly to patients by mail. This bypasses traditional safeguards, eliminating the required in-person medical consultation previously deemed essential for safety.
Data reveals a stark reality: chemical abortions now represent the majority – 63% in 2023 – a significant leap from 39% just six years prior. Estimates suggest over 500 of these procedures are now initiated through mail-order every single day.
The increase isn’t merely incremental. Analysis indicates roughly 170,000 more abortions occurred in 2024 than would have if rates had remained consistent with 2019 levels. This represents a 22% overall growth in abortions, while the U.S. population only grew by 2.9% during the same period.
The impact extends beyond state lines. Telehealth is facilitating access even in states with restrictive abortion laws, with over 120,000 pills shipped into those areas since the overturning of Roe v. Wade. This creates a complex legal landscape, as some states actively shield providers from prosecution.
Concerns center on the removal of critical safety standards. The policy change occurred despite limited studies and a pre-existing inadequacy in tracking complications related to the medication. Mandatory reporting requirements were actually diminished years earlier, hindering accurate safety evaluations.
Those familiar with the situation express alarm about potential risks. Reports suggest a significant number of women – approximately 150 daily – experience serious complications from the medication, ranging from sepsis and hemorrhaging to life-threatening ectopic pregnancies gone undetected.
The current trajectory is deeply concerning. Without intervention, projections estimate abortion numbers could reach 1.4 million annually by the end of a second Trump administration. This potential increase has prompted calls for immediate action from lawmakers and state officials.
The power to alter this course rests with the federal government. Advocates argue the Trump administration possesses the authority to reinstate the in-person dispensing requirement, a safeguard in place for two decades before its suspension. The question now is whether that authority will be exercised.
Beyond the political implications, a fundamental question of women’s health hangs in the balance. The debate isn’t solely about restricting access, but about ensuring safety and providing adequate medical oversight in a rapidly changing landscape.
A comprehensive safety review of the medication is underway, prompted by concerns raised by multiple state attorneys general. The results of this review, and the subsequent actions taken, will determine the future of abortion access and the well-being of countless women across the country.
